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Abstract. 
The treatment of multiple myeloma (MM) has made greatly advances over the last decade, 
nearly doubling the overall survival time after the use of novel agents such as thalidomide, le-
nalidomide and bortezomib. However, the improvement of overall survival has occasionally 
led to clinical scenarios that were rarely recognized before, for example, light chain escape and 
extramedullary plasmacytoma (EMP). Here we report an MM patient who relapsed and mani-
fested simultaneously with both a light chain escape and a disseminated pattern of EMP after 
several different modes of treatment, including conventional chemotherapy, autologous periph-
eral blood stem cell (PBSC) transplantation, and novel agents. The result was disappointing in 
this case, which taught us several important things: First, intact immunoglobulin may not be a 
reliable marker in the surveillance of pretreated multiple myeloma. Various tests for renal func-
tion, skeletal condition, and serum free light chain should also be carried out for a comprehen-
sive evaluation. Second, EMP remains a tremendous challenge to the clinician, especially when 
refractory to current novel agents. Further researches are required to clarify the optimal treat-
ment of such a condition in order to help more patients. 
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中文摘要 
  多發性骨髓瘤的治療在近幾年來蓬勃的發展，使得病患的存活時間幾乎延長至兩
倍，不過，存活時間的進步也導致一些原本不常見的臨床情況出現，” 輕鏈脫逃”和”髓外
漿細胞瘤”就是其中的代表。在這裡我們提出了一個多發性骨髓瘤的臨床案例，就是在接
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 受了包含傳統化療、自體幹細胞移植、以及標靶藥物後同時發生了這兩種現象，這個病
患的治療結果是令人失望的。但是我們從這個案例學到了一些經驗：第一、免疫球蛋白
的檢查在多發性骨髓瘤的監控上可能不是一個可靠的工具，需要合併腎功能檢查、骨骼
檢查、以及血漿游離輕鍊檢查，才能得到最好的監測效果；第二，髓外漿細胞瘤仍是一
個非常難治療的病症，仍有賴後續的研究來發展出真正有效的治療藥物，以幫助更多的
病患。 
 
關鍵字: 多發性骨髓瘤、輕鏈脫逃、髓外漿細胞瘤、新藥、血漿游離輕鏈檢查 
INTRODUCTION 
The treatment of multiple myeloma (MM) has 
made great advances over the last decade and has 
nearly doubled the overall survival time as compared 
to that of patients treated before 2000, primarily awing 
to the novel agents, including thalidomide, lenalido-
mide and bortezomib [1,2]. However, the improve-
ment of overall survival has occasionally led to clini-
cal scenarios that were rarely recognized before. One 
of these most difficult is the disease manifested or re-
lapsed as extramedullary plasmacytoma (EMP) in 
visceral organs, lymph nodes, and the central nervous 
system[3-10]. The presentations of such EMPs vary in 
different locations and most studies report a very dis-
appointing prognosis in this group of patients [3,4,11]. 
On the other hand, free light chain (FLC) concentra-
tion (in the serum) is a new assay method that used 
polyclonal antibodies against FLC to determine the 
serum concentration of free lambda and kappa light 
chains [12]. It has not only improved the diagnosis of 
myeloma, non-secretory MM [13], but also became a 
powerful tool to detect early relapse. Recently, light 
chain escape has been observed in some patients with 
former secretory MM after administration of chemo-
therapy [14], and in these patients the MM appeared 
stable as indicated by decreasing intact Ig levels, but 
they developed notable organ dysfunctions as a con-
sequence of unexpected light-chain MM progression. 
Here we report a MM patient who relapsed and mani-
fested simultaneously with both light chain escape and 
a disseminated pattern of EMP after several different 
modes of treatment, including conventional chemo-
therapy, autologous peripheral blood stem cell (PBSC) 
transplantation, and novel agents.  
CASE REPORT 
A 70-year-old Chinese female presented with left 
hip pain in February, 2010. She had a history of es-
sential hypertension under medical control for 20 
years. The X-ray of the left hip showed an osteolytic 
bone lesion, and subsequent studies. Investigating 
monoclonal gammopathy confirmed the diagnosis of 
IgA/lambda multiple myeloma, International Staging 
System stage 1, and Durie-Salmon stage II. At the 
time of diagnosis, the level of serum IgA was 2390 
mg/dL (normal range, 82 - 453), but serum FLC assay 
was not available at that time, as shown in Figure 1. 
She received induction chemotherapy with the VAD 
regimen (vincristine, doxorubicin and dexamethasone) 
for 6 cycles between March 2010 and September 2010. 
During the period, she also received zoledronic acid 
monthly and the harvest of PBSC. Autologous PBSC 
transplantation was performed on November 11, 2010. 
After transplantation, she received regular out-patient 
follow up, with laboratory monitoring including serum 
IgA, FLC assay and renal function tests (including 
creatinine [Cr]). A complete response was achieved 
one month after the transplantation, with the serum 
IgA level of 156 mg/dL (normal range, 82 - 453) and  
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Figure 1. The changes of serum IgA, free kappa/lambda ratio, creatinine and free lambda and treatments through 
the whole course of multiple myeloma. Two episodes of light chain escapes were noted in August 2011 
and October 2012 
 
 
serum FLC (Kappa/Lambda) ratio of 0.95 (normal 
range, 0.26-1.65), as shown in Figure 1. Maintenance 
therapy with thalidomide was asministrated, starting 
on day 71 post-transplantation, but stopping on June 
15, 2011 (day 201) because of the intolerance. The 
serum levels of Cr and IgA, and FLC ratio remained 
normal till August 2, 2011, when serum Cr (1.1 
mg/dL) and IgA (124 mg/dL) levels were within the 
normal range, but an increased lambda light chain 
level with an FLC ratio of 0.01 was found. Two weeks 
later, when she re-visited the out-patient department 
on August 16, 2011, acute renal failure with serum Cr 
increasing to 5.07 mg/dl, and the level of serum IgA 
surging to 900 mg/dl (reference range 82-453 mg/dl), 
and the bone marrow study confirmed the relapse of 
disease. According to the criteria described before 
[14], myeloma relapse with light chain escapes and 
resulting acute renal failure was diagnosed. Borte-
zomib was promptly started on August 20, 2011 and 
the serum Cr level returned to normal 2 months later. 
However, bortezomib therapy was discontinued in 
February 2012 because of peripheral neuropathy. 
Conventional chemotherapy with different combina-
tions including melphalan and dexamethasone, and 
cyclophosphamide and prednisolone was carried out 
thereafter to control the disease till October 2012. The 
second episode of light chain escapes was noted in 
October 2012, when the serum IgA level was normal 
(140 mg/dL), but the serum FLC ratio declined to 0.03 
on October 23, 2012. As was seen in the first event,  
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Figure 2. Extramedullary plasmacytoma manifested as two huge pedunculated polypoid masses, located in the 
high body (a) and fundus (b) of the stomach, both measuring 4 cm in diameter 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Histology of polypoid masses in the stom-
ach. The sections showed an inflammatory 
exudate and an aggregate of atypical plas-
ma cells with H&E stain (a), which were 
immunocytochemically positive for CD138 
(b) and Lambda light chain (c) 
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Figure 4. Sagittal views of abdominal CT showed variable-sized polypoid masses noted in gastric fundus 
and pars angularis of lesser sac of stomach; small soft tissue nodules in right renal fossa, right 
para-renal space and left posterior para-renal space; Ill-definted lobulated soft tissue nodules 
noted beside both common iliac arteries, right internal iliac artery, left external, internal iliac 
artery, uterus and bladder; and plasmacytoma encasing left ureter, resulting in proximal    
hydroureter and hydronephrosis 
 
 
acute renal failure was noted with serum Cr increasing 
from 1.07 mg/dl on September 25, 2012 to 4.83 mg/dl 
on November 20, 2012. Although bortezomib was 
given again to control the disease, the renal failure 
was not improved, and hemodialysis was soon initiat-
ed. The serum IgA level remained within the normal 
range and did not elevate, with the level at 518 mg/dL 
(normal range, 82 - 453) till January 21 2013. Fur-
thermore, progressive ileus and gastrointestinal (GI) 
bleeding were noted in late December 2012, with 
fresh-blood vomitus. Panendoscopy of the upper GI 
tract was performed and revealed two huge peduncu-
lated polyp-like masses in the high body and fundus of 
the stomach, each 4 cm in size (Figure 2A and 2B). 
The pathological examination of the biopsy confirmed 
plasmacytoma, which was immune-histochemically 
positive to lambda and CD138 (Figure 3). As the pa-
tient further suffered from the symptoms of progres-
sive abdominal distention and hematuria, a computed 
tomogram of the abdomen was taken in February 
2013 and showed disseminated plasmacytoma in-
volving the stomach, kidney, urinary bladder, uterus 
and retroperitoneum (Figure 4). Left hydronephrosis 
and hydroureter due to plasmacytoma encasing the left 
ureter was found. Although lenalidomide was given, 
pancytopenia and intermittent bleeding including 
vomiting of fresh blood, passage of bloody stools and 
hematuria were not well controlled. The renal failure 
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 did not recover. On April 26, 2013, the patient died of 
pneumonia. 
 
DISCUSSION 
Novel agents have improved the treatment out-
come of patients with multiple myeloma. However, 
prolonged survival has resulted in changes in the bio-
logical behavior of MM and unusual types of relapse, 
such as EMP or a shift in secretion from intact immu-
noglobulin (Ig) to free-light chains (FLCs) only [14]. 
Both of these phenomena simultaneously occurred in 
our patient. In the two episodes of acute renal failure, 
the serum FLC ratio had changed when the IgA still 
remained in the normal range. Acute renal failure rap-
idly developed later. The IgA level seemed to lose the 
power to predict the disease activity of the myeloma. 
Former researchers noticed such changes and denom-
inated the phenomenon as “the escape of myeloma” or 
“light chain escape” [15,16]. The findings in our pa-
tient further provide clues supporting the importance 
of simultaneous serum FLC monitoring of myeloma 
progression, instead of IgA detection alone. If not, we 
may overlook the early signs of disease relapse and 
miss the chance to save the patient’s life. One of the 
previous case series showed an aggressive disease 
course in such a group of patients [16], but another did 
not [14]. 
Aggressive EMP is another critical issue in the era 
of novel anti-myeloma agents. In our case, the patient 
received conventional chemotherapy with VAD and 
melphalan, autologous peripheral blood stem cell 
transplant, and novel agents including thalidomide and 
bortezomib before the occurrence of EMP. Although 
lenalidomide was administrated, the efficacy was lim-
ited. Papanikolaou et al. reported the incidence of ex-
tramedullary relapse of 9% in 303 Greek patients with 
MM [11], and these patients had a poor outcome. An-
other study in the US which enrolled 936 EMP pa-
tients demonstrated shorter progression-free survival 
and overall survival [3], when novel agents had been 
administered. On the other hand, previous case reports 
have demonstrated the efficacy of lenalidomide in re-
fractory EMP [17], or administration of thalidomide 
and bortezomib as induction and reinforced by autol-
ogous stem cell transplantation [5,18-20]. In addition, 
there was another case of primary EMP in the stomach 
that achieved a durable complete pathological re-
sponse after radical radiotherapy with minimal toxici-
ty [21]. Recently, the analysis of cytogenetic aberra-
tion of EMP using fluorescence in situ hybridization 
suggested the relevance of del(17p13) and del(13q14) 
to the “metastatic” feature of myeloma cells [22]. 
 
CONCLUSIONS 
To the best of our knowledge, this is the first re-
port to the record a case that had extramedullary 
plasmacytoma after light chain escape. The treatment 
result of this patient was disappointing; however we 
have learned something from this case: First, intact 
immunoglobulin may not be a reliable marker in the 
surveillance of pretreated multiple myeloma. Renal 
function, skeletal condition, and serum free light 
chains should also be examined for a comprehensive 
evaluation. Second, EMP remains a tremendous chal-
lenge to the clinician, especially when refractory to 
current novel agents. Further researches are necessary 
to clarify the optimal treatment of such a condition in 
order to help more patients. 
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